EurekaMag.com logo
+ Site Statistics
References:
47,893,527
Abstracts:
28,296,643
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Antiarrhythmic activity of oximethers






Acta Physiologica Hungarica 83(3): 223-226

Antiarrhythmic activity of oximethers

More than sixty 2-substituted-cycloalkanone-oxim-/2-hydroxy-3-dialkylamino/- propylethers were investigated on aconitine induced ventricular arrhythmia model in rats. According to the structure-activity relationships cyclohexanes containing diisopropylamine in the basic group were the most effective derivatives. Based on the highest per os activity and lowest toxicity EGIS-3966 (ED50 values 1.21 mg/kg iv. and 27.3 mg/kg per os) was selected for further development.


Accession: 009770217

PMID: 8852647



Related references

Raschack, M., 1976: Relationship of antiarrhythmic to inotropic activity and antiarrhythmic qualities of the optical isomers of verapamil. 1. The relationship of antiarrhythmic to inotropic activity of the optical isomers of verapamil was studied by comparing their effects on functional refractory period and force of contraction in the isolated left atrium of the guinea pig and on ma...

Hongjun J.; Liu X.; Yan Y.; Y.Y., 1987: Comparison of the antiarrhythmic activity of sodium valproate and classical antiarrhythmic drugs in animals. The LD50 of sodium valproate (VPA), propranolol (PRO), verapamil (VRP), lidocaine (LDC), quinidine (QND) and sodium phenytoin given to mice intravenously was determined. The antiarrhythmic action of these drugs on several models was compared at th...

Sokolov S.F.; Golitsyn S.P.; Malakhov V.I.; Bankuzov V.A.; Koltunova M.I.; Golitsyna L.S., 1990: The antiarrhythmic activity of the new antiarrhythmic drug bonnecor and its effect on the conductive system of the heart. In 10 patients with frequent ventricular extrasystoles there were studied the antiarrhythmic effectiveness and side effects of a new drug bonnecor at a single intravenous administration in doses from 15 to 60 mg (0.17-0.91 mg/kg). It was found tha...

Dhein, S.; Gottwald, M.; Kruesemann, K.; Tudyka, T.; Grover, R.; Klaus, W., 1997: Structure-activity relationships of antiarrhythmic peptides A new group of antiarrhythmic agents. Circulation 96(8 SUPPL ): I292, 10/21/97

Lindberg, U.H.; Akerman, B., 1985: Potential antiarrhythmic agents. II. Antiarrhythmic activity of basic N-(substituted phenyl and benzyl)dipeptides. Acta Pharmaceutica Suecica 22(6): 321-334

Argentieri, T.M.; Troy, H.H.; Carroll, M.S.; Doroshuk, C.M.; Sullivan, M.E., 1993: Electrophysiologic activity and antiarrhythmic efficacy of CK-3579, a new class III antiarrhythmic agent with beta-adrenergic blocking properties. CK-3579 (N-(4-(2-hydroxy-3-((2-(4-(1H-inidazol-1-yl)phenoxy)ethyl)amino)propoxy)phenyl)-methanesulfonamide, HCL-(RS)), is a new class III antiarrhythmic agent with beta-adrenoceptor blocking properties shown to be effective in preventing ventricul...

Koerner J.E.; Dage R.C., 1989: Antiarrhythmic activity of mdl 11939 a novel class iii antiarrhythmic agent. FASEB Journal 3(4): A1203

Filipek, B.; Sapa, J.; Malawska, B.; Kulig, K.; Antkiewicz-Michaluk, L., 1997: Search for new antiarrhythmic and hypotensive compounds. Synthesis, antiarrhythmic, antihypertensive, and alpha-adrenoceptor blocking activity of novel 1-[(2-hydroxy-3-amino)]-propylpyrrolidin-2-one derivatives. A series of the derivatives of 1-[2-hydroxy-3-(4-phenyl-1-piperazinyl])propyl]-pyrrolidin-2- one (MG-1) was synthesized and tested for electrocardiographic, antiarrhythmic, and antihypertensive activity as well as for alpha 1- and alpha 2-adrenoce...

Dhein, S.; Tudyka, T.; Schott, M.; Gottwald, E.; Salameh, A.; Rutten, P., 1996: Antiarrhythmic effects of antiarrhythmic peptide AAP10 in regional ischemia Improvement of cellular coupling as a new antiarrhythmic principle. Naunyn-Schmiedeberg's Archives of Pharmacology 354(4 SUPPL 1): R4

Allan, G.; Donoghue, S.; Follenfant, M.J.; Sawyer, D.A., 1986: BW A256C, a chemically novel class 1 antiarrhythmic agent. A comparison of in vitro and in vivo activity with other class 1 antiarrhythmic agents. BW A256C (5(3)-amino-6-(2,3-dichlorophenyl)-2,3(2,5)-dihydro-3(5)-imino-2 -isopropyl-1,2,4-triazine) is a novel class 1 antiarrhythmic agent designed to combine the features of potency with reduced central nervous system penetration. BW A256C redu...